GlassScriptPhysician profile
Kelly Yang
NPI 1215588991
$8,684.12
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,483 · 2022: $4,260 · 2023: $2,927 · 2024: $13.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,940.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,401.51 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $1,391.40 | 2022-2023 | Spravato, Invega Trinza, Invega |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $743.60 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $596.26 | 2022-2023 | Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $564.63 | 2021-2023 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $523.35 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $516.13 | 2021-2023 | Ingrezza |
| Indivior INC. | $470.85 | 2022-2023 | Perseris |
| Alkermes, INC. | $397.98 | 2021-2023 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $314.92 | 2021-2023 | Hetlioz, Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $293.87 | 2021-2023 | Trintellix |
| Lundbeck LLC | $269.53 | 2021-2023 | Rexulti |
| Livanova USA, INC. | $204.98 | 2021-2023 | Vns Therapy Symmetry Model 8103 Generator |
| Noven Therapeutics, LLC | $170.83 | 2022-2023 | Xelstrym, Secuado |
| Corium, LLC | $143.47 | 2023 | Azstarys |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $111.59 | 2021 | |
| Axsome Therapeutics, INC. | $111.58 | 2022-2023 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.05 | 2021 | |
| Glaxosmithkline, LLC. | $50.47 | 2021 | |
| Almatica Pharma LLC | $49.74 | 2023 | Loreev Xr, Sertraline Hcl |
| Eisai INC. | $43.56 | 2021 | |
| Amgen INC. | $33.59 | 2021 | |
| Merck Sharp & Dohme LLC | $28.85 | 2023 | Belsomra |
| Kowa Pharmaceuticals America, INC. | $24.68 | 2021 | |
| Sumitomo Pharma America, INC. | $24.21 | 2023 | Latuda |
| Owp Pharmaceuticals, INC. | $22.89 | 2023 | Lamotrigine, Subvenite |
| Biohaven Pharmaceuticals, INC. | $19.24 | 2021 | |
| Sk Life Science, INC. | $18.42 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.77 | 2021 | |
| Mannkind Corporation | $17.01 | 2021 | |
| Supernus Pharmaceuticals, INC. | $13.84 | 2024 | Qelbree |
| Tris Pharma INC | $13.32 | 2023 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.